Resitu: minimally invasive surgical technology

Addressing breast cancer management

Breast cancer is the world’s most prevalent cancer form. In 2020, almost eight million women had been living with breast cancer for the past five years, 2.3 million were diagnosed with breast cancer and the disease caused a staggering 685,000 deaths. Ref

The WHO’s Global Breast Cancer Initiative’s (GBCI) objective is to reduce the global breast cancer mortality rate by 2.5% per year. Ref

Breast cancer management

Any lesions detected by mammography need to be investigated. Today, a biopsy is taken and, if the lesion is cancerous, it is removed using open surgery.

The Resitu technology aims at removing the complete lesion already in the biopsy step, shortening the process by removing the need for open surgery.

Consultant Breast surgeon Andreas Karakatsanis at Uppsala University Hospital, Sweden:

“We see a rising demand for minimally invasive biopsy methods that facilitate the retrieval of larger tissue samples. That will minimize false negative results, and minimize the need for recalls and new biopsies.

The most important, however, is to fuse a diagnostic procedure with the removal of an intact lesion with high-quality margin assessment. This could yield the potential to change practice and help a large group of patients, not only with benign disease, but also with small cancers of the breast, to avoid surgery. That way, we could avoid overtreatment, enhance patient experience and mitigate burden for the healthcare system.”

Modern equipment for improved breast biopsy

Resitu is developing a minimally invasive, single-use, ultrasound guided device that uses diathermy to extract the tissue sample with minimal bleeding.

Colligo biopsy device for breast lesions

Resitu's first product in development is an electrosurgical instrument intended for sampling of breast tissue during a breast biopsy procedure.

Resitu

Resitu Medical AB
Rapsgatan 7B
Uppsala, Sweden

info@resitumedical.com

Resitu Medical AB is a Swedish Medical Device company founded in 2019. The company is developing instruments enabling safe removal of intact tissues by a revolutionary technology. The solution has the potential to create a paradigm shift in the management of breast cancer. The portfolio of instruments will speed up the process of cancer management using a minimally invasive approach and facilitating the way radiologists and surgeons work.

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.